Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Carleton

Showing results (1-10 of 108) with videos related to

Pageof 11
Sort By:
Therapeutic Drug Monitoring|May 26, 2010
Gene-based warfaring dosingBruce Carleton
Frontiers in Genetics|May 6, 2014
Pharmacogenomics and adverse drug reactions in childrenMichael J Rieder, Bruce Carleton
Current Pharmaceutical Design|September 2, 2015
New Ways of Detecting ADRs in Neonates and ChildrenRicardo Jimenez, Anne Smith, Bruce Carleton
Multiple Sclerosis and Related Disorders|April 17, 2015
The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosisKaarina Kowalec, Bruce Carleton, Helen Tremlett
Medical Care|October 25, 2007
Designed delays versus rigorous pragmatic trials: lower carat gold standards can produce relevant drug evaluationsMalcolm Maclure, Bruce Carleton, Sebastian Schneeweiss
Pharmacotherapy|March 14, 2019
Risk of Gynecomastia with Users of Proton Pump InhibitorsBonnie He, Bruce Carleton, Mahyar Etminan
Journal of Clinical Psychopharmacology|February 23, 2023
Reply: Misidentified Dopamine Agonists Undermine Investigation Into Aripiprazole Link With Impulse Control DisordersMahyar Etminan, Mohit Sodhi, Bruce Carleton
The American Journal of Clinical Nutrition|August 24, 2004
Formulas containing live probiotic bacteriaJamie Falk, Bruce Carleton, Patricia Gerber
Pharmacotherapy|May 10, 2019
Drs. He et al. Reply to Drs. Lai and BrownBonnie He, Bruce Carleton, Mahyar Etminan
Drug Safety|September 8, 2004
Quantifying adverse drug events : are systematic reviews the answer?Mahyar Etminan, Bruce Carleton, Paula A Rochon
Pageof 11

Showing results (1-10 of 108) with videos related to

Sort By:
Pageof 11
Therapeutic Drug Monitoring|May 26, 2010
Gene-based warfaring dosingBruce Carleton
Frontiers in Genetics|May 6, 2014
Pharmacogenomics and adverse drug reactions in childrenMichael J Rieder, Bruce Carleton
Current Pharmaceutical Design|September 2, 2015
New Ways of Detecting ADRs in Neonates and ChildrenRicardo Jimenez, Anne Smith, Bruce Carleton
Multiple Sclerosis and Related Disorders|April 17, 2015
The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosisKaarina Kowalec, Bruce Carleton, Helen Tremlett
Medical Care|October 25, 2007
Designed delays versus rigorous pragmatic trials: lower carat gold standards can produce relevant drug evaluationsMalcolm Maclure, Bruce Carleton, Sebastian Schneeweiss
Pharmacotherapy|March 14, 2019
Risk of Gynecomastia with Users of Proton Pump InhibitorsBonnie He, Bruce Carleton, Mahyar Etminan
Journal of Clinical Psychopharmacology|February 23, 2023
Reply: Misidentified Dopamine Agonists Undermine Investigation Into Aripiprazole Link With Impulse Control DisordersMahyar Etminan, Mohit Sodhi, Bruce Carleton
The American Journal of Clinical Nutrition|August 24, 2004
Formulas containing live probiotic bacteriaJamie Falk, Bruce Carleton, Patricia Gerber
Pharmacotherapy|May 10, 2019
Drs. He et al. Reply to Drs. Lai and BrownBonnie He, Bruce Carleton, Mahyar Etminan
Drug Safety|September 8, 2004
Quantifying adverse drug events : are systematic reviews the answer?Mahyar Etminan, Bruce Carleton, Paula A Rochon
Pageof 11